Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Visa to Move European Headquarters to London’s Canary Wharf 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
NEW YORK, Dec. 02, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of shareholders of Vital Therapies, Inc. (“Vital Therapies”) (NASDAQ:VTL) who purchased their shares between April 17, 2014 and August 21, 2015.
The complaint alleges that throughout the class period, defendants issued materially false and misleading statements and/or failed to disclose material information regarding the Company’s ELAD System studies, VTI-208, VTI-210, and VTI-212, including (a) the studies’ independent significance; (b) the degree to which the studies were interrelated; and (c) that in the case of the failure of the VTI-208 trial, the Company would not continue the VTI-210 trial.
On August 21, 2015, after the market closed, Vital Therapies announced that the VTI-208 trial had “failed to meet the primary endpoint of overall survival through at least 91 days…” and that the Company would stop the VTI-210 and VTI-212 clinical trials. Upon this news, Vital Therapies shares plunged 73.4% to close at just $3.65 per share the next trading day.
If you suffered a loss in Vital Therapies you have until February 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/vital-therapies.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
